Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic pancreatic ductal adenocarcinoma, drawn from the whole corpus: 274 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Resistance to RAS inhibitors emerges within months and the best partner drugs are unknown.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Checkpoint inhibitors fail outside mismatch repair deficient disease because the tumour excludes T cells.
Most patients are too unwell for FOLFIRINOX-type regimens and trials under-represent them.
Cachexia and thrombosis kill many patients before the cancer itself is the limiting problem.
Late diagnosis: half of patients present with metastases and no screening test exists for the general population.
Nothing recorded yet.
Background: CA 19-9. Also on OnCo: Symptoms and red flags · Early detection roadmap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 35 changes by month →When this page itself was last checked or edited.
OS 13.
Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.
A milestone in how this cancer is treated.
Objective response 30 percent across 158 evaluable NRG1 fusion-positive cancers, 42 percent (15 of 36) in pancreatic cancer; median duration of response 11.
Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.